London, UK – August 17, 2021 – Vortex Biosciences is making significant strides in the rapidly evolving liquid biopsy landscape, with its cutting-edge VTX-1 platform gaining recognition for its superior circulating tumour cell (CTC) isolation capabilities. Industry giants and emerging players alike are increasingly acknowledging the critical value of CTCs and their derived materials as key analytical tools in cancer diagnostics and personalized medicine. Vortex stands at the forefront of this innovation, poised to solidify its position in the research market and expand its clinical validity through advanced lab-developed tests. This pioneering technology also holds promise for other challenging applications, such as the isolation of rare foetal cells from maternal blood. Read more about it in a recent white paper.